home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Polymer Pumps Up Cancer Drug

  March, 2 2004 10:10
your information resource in human molecular genetics
An antitumor drug can be improved -- and made less toxic -- by linking it to a polymer, according to a report in the March issue of Nature Medicine.

Angiogenesis, or the building of new blood vessels, is essential for tumor growth. The drug TNP-470 slows tumor growth in clinical trials by blocking angiogenesis, but the drug can be toxic to patients. Judah Folkman and colleagues overcame the problem by linking TNP-470 to a water-soluble polymer.

The new 'conjugated' drug accumulated specifically in tumors, and slowed the growth of both skin and lung tumors in mice. But unlike free TNP-470, the conjugated drug did not affect motor coordination or the normal development of mice, and did not cross the blood-brain barrier. The authors suggest that conjugating drugs to polymers might be a new strategy for designing anticancer therapies.

Author contact:

Judah Folkman
Boston Children's Hospital
Boston, MA
Tel: +1 617 355 7661
E-mail: judah.folkman@tch.harvard.edu

Also available online.

(C) Nature Medicine press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.